Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries by Wong, Martin C.S. et al.
1SCIEnTIFIC RepoRtS |  (2018) 8:4522  | DOI:10.1038/s41598-018-19819-8
www.nature.com/scientificreports
Global Incidence and mortality 
of oesophageal cancer and their 
correlation with socioeconomic 
indicators temporal patterns and 
trends in 41 countries
Martin C. S. Wong1,2,8, Willie Hamilton3, David C. Whiteman4, Johnny Y. Jiang5, Youlin Qiao  5, 
Franklin D. H. Fung1, Harry H. X. Wang  6,7, Philip W. Y. Chiu2, Enders K. W. Ng2, Justin C. Y. 
Wu2,8, Jun Yu2,8, Francis K. L. Chan2,8 & Joseph J. Y. Sung2,8
Oesophageal cancers (adenocarcinomas [AC] and squamous cell carcinomas [SCC]) are characterized by 
high incidence/mortality in many countries. We aimed to delineate its global incidence and mortality, 
and studied whether socioeconomic development and its incidence rate were correlated. The age-
standardized rates (ASRs) of incidence and mortality of this medical condition in 2012 for 184 nations 
from the GLOBOCAN database; national databases capturing incidence rates, and the WHO mortality 
database were examined. Their correlations with two indicators of socioeconomic development were 
evaluated. Joinpoint regression analysis was used to generate trends. The ratio between the ASR of 
AC and SCC was strongly correlated with HDI (r = 0.535 [men]; r = 0.661 [women]) and GDP (r = 0.594 
[men]; r = 0.550 [women], both p < 0.001). Countries that reported the largest reduction in incidence 
in male included Poland (Average Annual Percent Change [AAPC] = −7.1, 95%C.I. = −12,−1.9) and 
Singapore (AAPC = −5.8, 95%C.I. = −9.5,−1.9), whereas for women the greatest decline was seen in 
Singapore (AAPC = −12.3, 95%C.I. = −17.3,−6.9) and China (AAPC = −5.6, 95%C.I. = −7.6,−3.4). 
The Philippines (AAPC = 4.3, 95%C.I. = 2,6.6) and Bulgaria (AAPC = 2.8, 95%C.I. = 0.5,5.1) had a 
significant mortality increase in men; whilst Columbia (AAPC = −6.1, 95%C.I. = −7.5,−4.6) and 
Slovenia (AAPC = −4.6, 95%C.I. = −7.9,−1.3) reported mortality decline in women. These findings 
inform individuals at increased risk for primary prevention.
Globally, oesophageal cancer is one of the most frequently reported malignancies and a leading cause of cancer 
deaths1. In 2008, the disease accounted for around 4 million disability-adjusted life years2. The cancer is extremely 
aggressive and prognosis is often poor3,4.
Majority of oesophageal cancers (80%) are reported in more deprived nations. Most of these cancers belong 
to either of the major histologic types: squamous cell carcinoma (SCC) and adenocarcinoma (AC). Although 
SCCs historically consist of the majority of all cases of this cancer, in recent years we have observed a rapid rise 
of AC in western countries3,5. The risk factors of AC such as increased age, male sex, obesity, gastro-oesophageal 
reflux disease, cigarette smoking, and diet low in vegetables and fruit have been widely recognized; whereas for 
SCC, cigarette smoking, alcohol consumption, caustic injury, poor oral hygiene, ingestion of caustic agents, and 
nutritional deficiencies are major risk factors3,6. As many risk factors of oesophageal cancer could be modified, 
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it should be possible to control this disease by preventive measures7. Therefore, it is important to examine its 
updated rates of incidence and mortality, particularly with respect to temporal trends.
Prior evaluations studying its global trends are based on figures in late 1990s6–8; have not taken country-specific 
socioeconomic development when the trends were compared6–9, or compared the incidence/mortality trends in 
one or few selected years10. It remains unknown whether the effect of socioeconomic status on the development 
of SCC vs. AC is different in different countries. In some western countries surveillance of Barrett’s esophagus is 
offered, though a tiny fraction of the total burden of oesophageal cancer arises from Barrett’s esophagus.
This study aimed to analyze its global patterns and temporal trends of oesophageal cancer by retrieval of data 
from national databases. We examined the incidence ratio between AC and SCC and its correlation with socioec-
onomic development across various countries on a global basis.
Methodology
Data retrieval. Estimates of incidence and mortality rates of oesophageal cancer were collected from the 
GLOBOCAN database for 20121. The disease coding is ICD-10 C15. We used a study approach similar to recent 
evaluations on prostate, liver, bladder and pancreatic cancer11–14. Figures of the Gross Domestic Product (GPD) 
and Human Development Index (HDI) for each nation were obtained15, and incidence/mortality figures from 
GLOBOCAN of the same year1. HDI is determined by income per capita, period of education and life expectancy15. 
We extracted data from various sources, and restricted to those databases with no less than 15 calendar years of inci-
dence/mortality figures. For incidence data, we retrieved country-specific registries based on the Cancer Incidence 
in Five Continents (CI5) volumes I-X16. With an aim to obtain the most updated figures, we used data from the 
United States17 and Europe (European Cancer Observatory and NORDCAN) which are publicly available18,19. These 
databases, including GLOBOCAN, have been used extensively in studies examining the incidence trends of vari-
ous cancers on a global basis (Supplementary Table 1). Data provided by these databases are comprehensive, and 
have been recognized as the standards for quality among cancer registries1,17–22. Supplementary Table 2 shows the 
methods by which the data were obtained and their quality. Based on the International Classification of Diseases 10th 
revision (ICD-10 C15), we categorized incidence data into various groups. Data on mortality were categorized using 
ICD 9th (150·0) up to 1991 and 10th version (C15) thereafter. The incidence of AC and SCC in 2012 was obtained 
based on the ICD for Oncology-3 presented in CI510,16,23: ACs: 8140–8141, 8143–8145, 8190–8231, 8260–8263, 
8310, 8401, 8480–8490, 8550–8551, 8570–8574, 8576; SCC: 8050–8078 and 8383–8084. To obtain mortality figures, 
the WHO mortality data series were used. We only included data with quality that reached medium level or above24, 
so that complete and accurate data with wide coverage could be analyzed. The database used death certificates to 
ascertain causes of death. The ASRs were based on the standard population of the world25. More developed nations 
were defined as European nations, New Zealand, Australia and Northern America as well as Japan, while other 
countries and regions were considered as less developed nations1.
Study Design. To correlate rates of incidence and mortality vs. the socioeconomic indices (HDI/GDP per 
capita), a cross-sectional association study was performed. To examine the incidence/mortality trends in vari-
ous nations based on Average Annual Percent Change (AAPC), we adopted a retrospective review of published 
age-standardized incidence/mortality rates from international or national data registries by joinpoint regression.
Statistical Analysis. The ASRs of incidence and mortality, as well as the AC: SCC incidence ratios of each 
country10 were correlated with the two socioeconomic indicators. We used simple linear regression and exam-
ined the goodness-of-fit, which were represented by correlation coefficients. We employed regression analysis 
via joinpoints to evaluate the trends of incidence/mortality26. We conducted logarithmic transformation of the 
incidence/mortality rates and calculated standard errors approximated binomially. We specified a maximum of 3 
joinpoints was specified as the analysis option. The intervals of average annual percentage change (AAPC) were 
evaluated. We calculated the AAPC as an average of APCs by geometric weighting. Weights equal to the length 
of each segment were assigned for the time interval specified27. We compared the magnitude of AAPC with zero 
which could generate the statistical significance of AAPC, and we defined a trend as stable if the AAPC was insig-
nificant. We considered all p values < 0·05 as reaching statistical significance. This study obtained ethics approval 
from the Survey and Behavioral Research Ethics Committee of CUHK.
Results
Incidence, mortality and histologic subtype ratios of esophageal cancer. In 2012, there were 
455,784 new diagnoses of oesophageal cancer and 400,169 mortality related to the cancer (Tables 1/ and 2). 
Around 81% of incident cases and 82% of all mortality were reported in underdeveloped nations. Rates of inci-
dence and mortality were greater in relatively less resourced regions than less deprived countries by 1·5 to 1·7-
fold in men, and by 3·4 to 4-fold in women. On a global basis, the rates of incidence varied by 20-fold. Among 
male, the highest rates of incidence were reported in Eastern Asia (with ASR = 16·9 per 100,000), Southern 
Africa (13·7), Eastern Africa (11·9) and Northern Europe (8·1), and the lowest in Western Africa (0·8), Central 
America (1·7), Northern Africa (2·4) and Western Asia (2·9) (Table 1). In female individuals, the greatest rates 
were reported in middle Africa (ASR per 10,000 = 7·8), Western Africa (6·7), Eastern Asia (5·4) and Eastern 
Africa (4·2), while the lowest in Micronesia/Polynesia (0·2), Southern Europe (0·6), Central America (0·6) and 
South-Eastern Asia (1·0). The results were shown in Table 2.
In 2012, the variation of rates of mortality was approximately 10-fold on a global basis. In male, the highest 
rate of mortality were estimated in the Eastern Asia (14·1), Western Africa (12·8) and middle Africa (11·2); while 
in female, the highest death rate was observed in these three regions (ASR of mortality = 4·5, 6·2 and 7·3 per 
100,000, respectively). The lowest rates of mortality were reported in Central America (1·6), Southern Africa 
(2·3), and Western Asia (2·7) in men. For women, Central America (0·5) and South-Eastern Asia (0·9) reported 
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the lowest rates of mortality. Regions with the largest incidence: mortality ratio in men included Southern Africa 
(1·47), Western Europe (1·27), and South America (1·23). In women, the highest ratios were reported for female 
in Western Europe (3·57), Northern Europe (1·63) and South America (1·34).
Table 3 shows the ratio between the incidence of AC and SCC in all countries where data were available10. The 
AC:SCC ratios were in general higher in male individuals. Countries in Eastern and South-East Asia, as well as 
sub-Saharan Africa had low AC:SCC ratios. When compared with SCC, many countries in the Northern America 
(e.g. Canada, the US), Northern Europe and Western Europe such as the Netherlands, UK, and Ireland had larger 
incidence of AC in men.
Correlation: rates of incidence/mortality vs. HDI and GDP per capita. The incidence of AC 
increased with HDI in men (r2 = 0·224, r = 0·473) and women (r2 = 0·037, r = 0·192), and similarly for its rela-
tionship with GDP (r2 = 0·288, r = 0·537 and r2 = 0·0716, r = 0·268 for male and female, respectively). For SCC, 
its incidence was inversely correlated with HDI (r2 = 0·051, r = −0·226, p = 0·004 for men; r2 = 0·098, r = −0·313, 
p < 0·001 for women) and GDP per capita (r2 = 0·040, r = −0·200, p = 0·012 for men; r2 = 0·0437, r = −0·209, 
p = 0·009 for women) (Fig. 1A to D). HDI was correlated with the ratio between the standardized incidence of AC 
and SCC (r² = 0·287, r = 0·535 [men]; r² = 0·437, r = 0·661 [women]) and GDP per capita (r² = 0·353, r = 0·594 
[men]; r² = 0·302, r = 0·550 [women], all p < 0·001). Similar trend was observed when the ratio between the abso-
lute incidence of AC and SCC was used (Fig. 2A to D).
Time trends. The global trends of incidence and mortality according to gender were shown in Supplementary 
Figure 1. Among male subjects, 3 countries reported increasing incidence, 7 countries reported decreasing inci-
dence, and 31 countries had stable rates of incidence. Among women, one country showed increasing incidence 
and 4 showed declining incidence. Turning to mortality rates, 2 countries had increasing trends, 10 countries 
reported decreasing male mortality and 29 nations reported relatively stable time trends in male subjects. Five 
countries had decreasing death rates and 36 countries had stable death rates in female populations.
Latin America/the Caribbean. All countries in this continent had stable incidence trends in the past decade of 
analysis (Fig. 3A). The ASR mortality rate reported a decline in Brazilian men (AAPC −1.2, 95% C.I. −1.5, −0.8) 
World regions Population Male (1,000)
Incidence Mortality
Incidence to mortality ration ASR n ASR
Africa 549,445 16,062 5.6 14,702 5.3 1.09
Eastern Africa 180,243 9,805 11.9 12,982 6.4 0.76
Middle Africa 69,179 1,202 4.2 8,944 11.2 0.13
Northern Africa 106,147 1,864 2.4 1,109 4.0 1.68
Southern Africa 29,735 2,523 13.7 1,720 2.3 1.47
Western Africa 164,141 668 0.8 2,320 12.8 0.29
Asia 2,179,003 240,142 11.4 207,984 9.9 1.15
Eastern Asia 813,296 183,024 16.9 155,262 14.1 1.18
South-Eastern Asia 305,225 9,366 3.6 8,545 3.3 1.10
South-Central Asia 933,786 45,315 6.5 41,922 6.0 1.08
Western Asia 126,697 2,437 2.9 2,255 2.7 1.08
America* 303,514 30,350 5.5 26,996 4.8 1.12
Caribbean 20,951 1,056 4.6 954 4.1 1.10
Central America 82,227 1,141 1.7 1,054 1.6 1.08
South America 200,336 13,286 7.0 10,773 5.6 1.23
North America 173,209 14,867 5.4 14,215 5.0 1.05
Europe 355,275 35,100 5.8 30,335 4.9 1.16
Central and Eastern Europe 138,249 11,044 5.6 9,892 5.0 1.12
Northern Europe 49,574 7,618 8.1 6,951 7.2 1.10
Southern Europe 74,900 4,516 3.2 4,091 2.8 1.10
Western Europe 92,553 11,922 6.8 9,401 5.0 1.27
Oceania 18,859 1,354 5.2 1,200 4.5 1.13
Australia/New Zealand 13,632 1,251 5.4 1,106 4.7 1.13
Melanesia 4,628 86 3.6 77 3.4 1.12
Micronesia/Polynesia 258 17 3.1 17 3.2 1.00
More developed regions 604,008 67,748 6.4 56,099 5.2 1.21
Less developed regions 2,975,297 255,260 10.1 225,118 9.0 1.13
World 3,579,305 323,008 9.0 281,217 7.7 1.15
Table 1. Age standardized incidence/mortality of cancer of oesophagus in various regions (male). ASR = Age 
standardized rate per 100,000 in 2012. Source: GLOBOCAN 2012. Numbers are rounded to the nearest 10 or 
100, and may not add up to the total. *America = WHO Americas region (PAHO).
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and women (AAPC −1.6, 95% C.I. −2.3, −0.9). Columbia also had a significant reduction in mortality among 
men (AAPC −4.6, 95% C.I. −5.8, −3.4) and women (AAPC −6.1, 95% C.I. −7.5, −4.6) (Fig. 3B).
Northern America. A reduction in incidence was reported in male (AAPC −5·3, 95% C.I. −6·6, −3·9) and 
female (AAPC −4·6, 95% C.I. −8·5, −0·4) Black American individuals. A modest reduction in death rates was 
observed among male populations (AAPC −1·2, 95% C.I. −1·6, −0·8) and women (AAPC −1·7, 95% C.I. −2·4, 
0·9) in the United States irrespective of ethnicity.
Asia. China (AAPC −5·3, 95% C.I. −6·5, −4), Singapore (AAPC −5·8, 95% C.I. −9·5, −1·9) and Israel (AAPC 
−3·2, 95% C.I. −5·1, −1·3) reported an incidence reduction in male, and the former two also experienced a decrease 
in female (China: AAPC −5·6, 95% C.I. −7·6, −3·4; Singapore: AAPC −12·3, 95% C.I. −17·3, −6·9). There was a 
substantial decline in mortality in Japanese men (AAPC −2·3, 95% C.I. −3. 2, −1·5)  and women (AAPC −0.8, 95% 
C.I. −1.6, 0).
Oceania. The incidence decreased in Australia in female subjects (AAPC −2·5, 95% C.I. −3·8, −1·2). All other 
trends were stable.
Northern Europe. Only the United Kingdom (AAPC 1·4, 95% C.I.0·9, 1·9) and Denmark (AAPC 2.9, 95% C.I. 
1.1, 4.7) reported an incidence increase among male. The United Kingdom also showed a mortality reduction 
among both male (AAPC −0·6, 95% C.I. −0·9, −0·3) and female (AAPC −1·6, 95% C.I. −2·2, −1·1). The major-
ity of the countries had stable incidence and mortality rates.
Western Europe. The incidence rate was found to increase in the Netherlands in male populations (AAPC 3, 
95% C.I. 2, 4) and female (AAPC 2·3, 95% C.I. 1·3, 3·2) individuals. France reported a decline in incidence (AAPC 
−3·7, 95% C.I. −5, −2·5) and mortality rates (AAPC −3·4, 95% C.I. −3·9, −2·9) among men.
Southern Europe. Italy and Croatia were two countries that had declines in incidence and mortality rates in male 
populations. Slovenia showed a decline in mortality among women (AAPC −4·6, 95% C.I. −7·9, −1·3).
World regions Population Female (1,000)
Incidence Mortality
Incidence to mortality ration ASR n ASR
Africa 549,608 11,459 3.5 10,542 3.3 1.09
Eastern Africa 182,469 10,211 4.2 9,391 3.9 1.09
Middle Africa 69,644 7,468 7.8 6,860 7.3 1.09
Northern Africa 105,353 681 2.0 630 1.8 1.08
Southern Africa 30,816 1,248 1.5 1,151 1.4 1.08
Western Africa 161,327 1,719 6.7 1,582 6.2 1.09
Asia 2,081,150 100,333 4.3 90,735 3.8 1.11
Eastern Asia 777,374 66,899 5.4 59,860 4.5 1.12
South-Eastern Asia 306,008 2,942 1.0 2,659 0.9 1.11
South-Central Asia 881,514 28,498 3.9 26,370 3.6 1.08
Western Asia 116,253 1,994 2.1 1,846 1.9 1.08
America* 310,360 9,640 1.4 8,007 1.1 1.20
Caribbean 21,313 343 1.2 291 1.0 1.18
Central America 83,632 462 0.6 429 0.5 1.08
South America 205,415 4,892 2.0 3,660 1.5 1.34
North America 176,585 3,943 1.1 3,627 1.0 1.09
Europe 381,747 10,793 1.2 9,201 0.9 1.17
Central and Eastern Europe 155,701 2,608 0.8 7,427 1.1 0.35
Northern Europe 51,252 3,474 2.7 2,136 0.6 1.63
Southern Europe 78,393 1,119 0.6 3,121 2.3 0.36
Western Europe 96,400 3,592 1.6 1,006 0.5 3.57
Oceania 18,746 551 1.7 467 1.4 1.18
Australia/New Zealand 13,715 507 1.7 424 1.3 1.20
Melanesia 4,451 43 1.4 42 1.4 1.02
Micronesia/Polynesia 580 1 0.2 1 0.2 1.00
More developed regions 637,294 18,396 1.2 15,249 0.9 1.21
Less developed regions 2,880,901 114,380 4.1 103,703 3.6 1.10
World 3,518,195 132,776 3.1 118,952 2.7 1.12
Table 2. Age standardized incidence/mortality of cancer of oesophagus in various regions (female). ASR = Age 
standardized rate per 100,000 in 2012. Source: GLOBOCAN 2012. Numbers are rounded to the nearest 10 or 
100, and may not add up to the total. *America = WHO Americas region (PAHO).
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Male Female
AC:SCC ratio (male) AC:SCC ratio (female)
AC SCC AC SCC
ASR N ASR N ASR N ASR N
Sub-Saharan Africa
Angola 0.3 12 5.9 238 0.2 7 3.3 155 0.050 0.045
Benin 0.1 1 1.3 31 0.0 0 0.3 7 0.032 0.000
Botswana 0.8 5 14.4 86 0.2 2 4.0 30 0.058 0.067
Burkina Faso 0.1 3 2.0 51 0.0 2 1.2 58 0.059 0.034
Burundi 1.0 17 17.8 343 0.4 9 7.8 198 0.050 0.045
Cameroon 0.1 3 1.4 77 0.0 1 0.6 40 0.039 0.025
Cape Verde 0.0 0 0.3 1 0.0 0 0.0 0 0.000 0.000
Central African Republic 0.2 2 2.7 32 0.1 1 1.7 26 0.063 0.038
Chad 0.1 3 2.0 54 0.1 2 1.4 44 0.056 0.045
Comoros 0.7 1 11.8 21 0.3 1 6.6 13 0.048 0.077
Congo, Democratic Republic of 0.3 37 5.1 697 0.1 17 2.2 370 0.053 0.046
Congo, Republic of 0.1 1 1.4 14 0.0 0 0.2 3 0.071 0.000
Cote d Ivoire 0.1 6 1.5 93 0.0 1 0.4 25 0.065 0.040
Djibouti 0.2 0 3.6 9 0.2 0 3.8 11 0.000 0.000
Equatorial Guinea 0.1 0 2.1 7 0.0 0 0.3 1 0.000 0.000
Eritrea 0.2 2 3.8 39 0.2 3 4.5 66 0.051 0.045
Ethiopia 0.1 21 1.9 466 0.2 46 4.4 1077 0.045 0.043
France, La Reunion 0.4 2 7.8 36 0.0 0 0.4 3 0.056 0.000
Gabon 0.1 1 2.9 15 0.1 0 1.5 9 0.067 0.000
Ghana 0.0 3 0.8 68 0.0 1 0.2 17 0.044 0.059
Guinea 0.1 1 0.8 19 0.0 0 0.1 4 0.053 0.000
Guinea-Bissau 0.0 0 0.8 3 0.0 0 0.0 0 0.000 0.000
Kenya 1.1 92 19.3 1767 0.7 67 14.3 1481 0.052 0.045
Lesotho 1.1 6 19.8 101 0.5 4 10.6 81 0.059 0.049
Liberia 0.1 1 1.1 9 0.0 0 0.2 3 0.111 0.000
Madagascar 0.6 30 10.6 593 0.2 12 4.3 267 0.051 0.045
Malawi 1.4 51 26.5 1015 0.9 38 19.8 851 0.050 0.045
Mali 0.1 2 1.4 51 0.0 1 0.4 20 0.039 0.050
Mauritania 0.1 0 1.1 10 0.0 0 0.1 1 0.000 0.000
Mauritius 0.3 2 4.2 28 0.1 1 2.1 19 0.071 0.053
Mozambique 0.6 35 11.8 685 0.3 23 6.7 493 0.051 0.047
Namibia 0.1 1 2.2 13 0.0 0 0.5 4 0.077 0.000
Niger 0.1 2 1.1 48 0.0 0 0.2 7 0.042 0.000
Nigeria 0.0 7 0.3 137 0.0 7 0.3 133 0.051 0.053
Rwanda 0.5 11 8.8 208 0.2 5 4.2 119 0.053 0.042
Senegal 0.1 2 1.1 32 0.0 0 0.3 12 0.063 0.000
Sierra Leone 0.1 1 1.2 12 0.0 0 0.3 3 0.083 0.000
Somalia 0.6 12 10.6 238 0.4 10 9.3 233 0.050 0.043
South African Republic 1.0 163 12.9 2121 0.7 162 6.2 1425 0.077 0.114
South Sudan 0.6 16 11.0 298 0.3 10 7.0 210 0.054 0.048
Swaziland 0.5 1 9.1 25 0.1 0 2.9 10 0.040 0.000
Tanzania 0.7 70 12.2 1288 0.3 36 5.8 763 0.054 0.047
The Gambia 0.1 0 1.0 5 0.0 0 0.0 0 0.000 0.000
Togo 0.2 4 3.8 61 0.1 2 1.9 37 0.066 0.054
Uganda 1.3 79 23.3 1518 0.5 36 9.8 726 0.052 0.050
Zambia 0.6 17 10.4 311 0.3 11 7.1 240 0.055 0.046
Zimbabwe 2.6 90 9.0 306 0.9 40 7.1 289 0.294 0.138
Northern Africa & Western Asia
Algeria 0.3 38 0.6 84 0.0 6 0.3 39 0.452 0.154
Armenia 0.7 12 1.5 26 0.1 3 0.5 18 0.462 0.167
Azerbaijan 1.9 78 4.2 171 0.5 26 2.8 160 0.456 0.163
Bahrain 1.5 4 0.7 3 0.3 1 1.0 2 1.333 0.500
Egypt 0.5 164 2.3 736 0.3 102 1.2 439 0.223 0.232
Gaza Strip and West Bank 0.3 10 0.7 22 0.0 2 0.3 13 0.455 0.154
Continued
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Male Female
AC:SCC ratio (male) AC:SCC ratio (female)
AC SCC AC SCC
ASR N ASR N ASR N ASR N
Georgia 0.4 30 1.0 67 0.1 12 0.8 78 0.448 0.154
Iraq 0.9 47 0.7 37 0.2 14 0.6 40 1.270 0.350
Israel 0.4 7 0.8 15 0.1 2 0.5 9 0.467 0.222
Jordan 0.2 2 0.5 5 0.1 1 0.8 3 0.400 0.333
Kuwait 0.3 6 0.6 13 0.1 2 0.5 13 0.462 0.154
Lebanon 0.5 10 1.1 23 0.0 1 0.2 7 0.435 0.143
Libya 0.5 66 1.1 145 0.1 17 0.7 104 0.455 0.163
Morocco 0.6 4 1.2 9 0.2 1 1.0 6 0.444 0.167
Oman 0.6 3 1.2 6 0.4 1 2.5 3 0.500 0.333
Qatar 0.4 39 1.0 82 0.2 11 1.3 93 0.476 0.118
Saudi Arabia 0.7 7 1.6 15 0.1 1 0.7 7 0.467 0.143
Sudan 1.8 169 4.0 373 0.6 66 4.1 434 0.453 0.152
Syrian Arab Republic 0.4 26 0.9 58 0.1 7 0.7 45 0.448 0.156
Tunisia 0.2 9 0.4 20 0.1 4 0.4 24 0.450 0.167
Turkey 1.1 352 3.1 1022 0.2 82 2.8 1059 0.344 0.077
United Arab Emirates 0.5 7 1.2 16 0.4 2 2.2 14 0.438 0.143
Western Sahara 0.1 0 0.3 1 0.0 0 0.0 0 0.000 0.000
Yemen 1.4 63 3.0 137 0.6 34 3.8 223 0.460 0.152
Central Asia
Afghanistan 1.3 84 10.5 712 0.5 33 7.0 490 0.118 0.067
Bangladesh 1.7 901 14.1 7619 0.6 339 8.9 4987 0.118 0.068
Bhutan 0.7 2 5.8 17 0.3 1 4.5 12 0.118 0.083
India 0.4 2174 4.9 24855 0.1 680 2.6 13884 0.087 0.049
Iran, Islamic Republic of 0.9 272 8.2 2626 0.9 253 7.2 2192 0.104 0.115
Kazakhstan 1.7 103 14.0 856 0.5 51 6.2 666 0.120 0.077
Kyrgyzstan 0.7 11 6.1 96 0.2 5 3.2 73 0.115 0.068
Maldives 0.6 1 5.3 6 0.2 0 2.4 3 0.167 0.000
Nepal 0.4 35 3.2 292 0.1 12 1.5 164 0.120 0.073
Pakistan 0.4 257 3.5 2180 0.3 169 4.1 2541 0.118 0.067
Sri Lanka 0.6 71 5.0 592 0.4 50 5.1 688 0.120 0.073
Tajikistan 2.1 36 17.5 304 0.7 15 10.0 212 0.118 0.071
Turkmenistan 2.6 40 21.3 341 1.1 22 15.2 312 0.117 0.071
Uzbekistan 0.8 67 6.4 557 0.3 36 4.7 515 0.120 0.070
Eastern/South-East Asia
Brunei 0.0 0 0.4 1 0.1 0 1.1 1 0.000 0.000
Cambodia 0.2 7 3.9 152 0.1 3 1.2 72 0.046 0.042
China 0.8 7009 17.5 151146 0.3 2489 6.3 59639 0.046 0.042
Indonesia 0.1 67 1.4 1427 0.0 33 0.6 637 0.047 0.052
Japan 0.4 633 10.5 15640 0.1 164 1.6 2897 0.040 0.057
Korea, Democratic Republic of 0.4 54 9.0 1157 0.1 21 1.8 366 0.047 0.057
Korea, Republic of 0.2 78 5.7 1925 0.0 21 0.4 166 0.041 0.127
Lao PDR 0.0 1 0.9 16 0.0 0 0.3 8 0.063 0.000
Malaysia 1.0 121 1.5 177 0.5 62 1.0 123 0.684 0.504
Mongolia 1.0 8 19.9 156 0.8 8 13.9 140 0.051 0.057
Myanmar 0.5 99 10.8 2312 0.2 42 3.9 943 0.043 0.045
Philippines 0.6 154 1.2 345 0.1 50 0.4 143 0.446 0.350
Singapore 0.3 12 2.5 92 0.1 3 0.5 26 0.130 0.115
Thailand 0.3 114 4.1 1743 0.1 39 0.8 391 0.065 0.100
Timor-Leste 0.1 0 2.4 8 0.1 0 0.8 2 0.000 0.000
Central and Southern America & Caribbean
Argentina 2.0 473 4.2 1020 0.4 163 1.7 603 0.464 0.270
Bahamas 0.6 1 2.1 4 0.1 0 0.4 1 0.250 0.000
Barbados 0.8 2 2.5 5 0.2 1 0.5 2 0.400 0.500
Belize 0.9 1 3.2 3 0.3 0 1.2 2 0.333 0.000
Bolivia 0.3 10 1.0 33 0.1 3 0.3 11 0.303 0.273
Continued
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Male Female
AC:SCC ratio (male) AC:SCC ratio (female)
AC SCC AC SCC
ASR N ASR N ASR N ASR N
Brazil 2.0 1873 8.1 7804 0.6 706 2.1 2469 0.240 0.286
Chile 0.7 78 4.1 441 0.3 39 1.5 230 0.177 0.170
Colombia 1.1 216 1.9 357 0.2 53 0.9 220 0.605 0.241
Costa Rica 0.8 18 1.2 28 0.2 4 0.4 13 0.643 0.308
Cuba 1.7 147 6.0 510 0.4 39 1.3 132 0.288 0.295
Dominican Republic 0.4 19 1.3 63 0.3 12 0.9 40 0.302 0.300
Ecuador 0.3 23 1.1 78 0.2 16 0.3 24 0.295 0.667
El Salvador 0.5 15 1.6 44 0.1 6 0.5 21 0.341 0.286
France, Guadeloupe 1.3 4 4.5 15 0.2 1 0.7 2 0.267 0.500
France, Martinique 1.0 3 3.5 11 0.1 1 0.4 2 0.273 0.500
French Guyana 1.4 1 4.8 5 0.0 0 0.0 0 0.200 0.000
Guatemala 0.5 22 1.6 72 0.3 13 0.9 45 0.306 0.289
Guyana 0.6 1 1.9 5 0.1 0 0.4 2 0.200 0.000
Haiti 0.5 17 1.8 62 0.3 12 1.0 39 0.274 0.308
Honduras 0.5 11 1.5 36 0.1 4 0.4 13 0.306 0.308
Jamaica 0.9 13 2.9 40 0.2 3 0.6 10 0.325 0.300
Mexico 0.4 190 1.2 623 0.1 74 0.4 247 0.305 0.300
Nicaragua 0.4 7 1.4 23 0.0 0 0.1 2 0.304 0.000
Panama 0.6 10 1.8 31 0.2 3 0.5 11 0.323 0.273
Paraguay 1.0 26 3.5 89 0.3 8 1.0 27 0.292 0.296
Peru 0.5 57 1.4 180 0.1 22 0.5 74 0.317 0.297
Puerto Rico 0.9 25 2.4 64 0.3 10 0.5 23 0.391 0.435
Suriname 0.3 1 0.9 2 0.1 0 0.5 2 0.500 0.000
Trinidad and Tobago 0.5 3 1.7 11 0.0 0 0.0 0 0.273 0.000
Uruguay 2.1 51 6.6 157 0.6 26 2.1 78 0.325 0.333
Venezuela 0.5 57 1.5 192 0.1 19 0.4 65 0.297 0.292
Northern America
Canada 3.0 898 1.5 462 0.4 158 0.7 269 1.944 0.587
United States of America 3.6 8785 1.8 4334 0.4 1309 0.7 2090 2.027 0.626
Eastern Europe
Belarus 0.8 50 5.9 356 0.1 12 0.3 29 0.140 0.414
Bulgaria 0.9 55 2.1 125 0.1 13 0.3 26 0.440 0.500
Czech Republic 2.2 188 3.4 285 0.3 36 0.7 73 0.660 0.493
Hungary 1.3 94 5.6 407 0.2 25 0.7 70 0.231 0.357
Poland 0.5 148 3.4 989 0.1 43 0.7 311 0.150 0.138
Republic of Moldova 0.7 15 2.7 62 0.1 2 0.1 4 0.242 0.500
Romania 0.8 121 3.5 527 0.1 31 0.4 80 0.230 0.388
Russian Federation 0.8 699 5.6 4953 0.1 232 0.7 1268 0.141 0.183
Slovakia 0.8 29 5.6 209 0.2 8 0.7 34 0.139 0.235
Ukraine 0.9 271 4.5 1339 0.2 91 0.3 165 0.202 0.552
Northern and Western Europe
Austria 2.0 150 3 216 0.2 24 0.5 50 0.694 0.480
Belgium 3.5 351 3.9 359 0.6 80 1.4 159 0.978 0.503
Denmark 3.1 169 2.4 122 0.8 50 1.5 91 1.385 0.549
Estonia 0.4 4 4 38 0.1 1 0.5 10 0.105 0.100
Finland 1.8 94 1.8 96 0.3 25 0.8 60 0.979 0.417
France (metropolitan) 1.6 886 4.4 2331 0.3 264 1.4 873 0.380 0.302
Germany 2.2 1789 4.7 3659 0.3 334 1.1 1050 0.489 0.318
Iceland 3.9 10 2.7 7 0.6 2 0.8 3 1.429 0.667
Ireland 5.4 183 2.9 95 1 44 2.2 94 1.926 0.468
Latvia 0.9 15 6.2 97 0.2 6 0.9 24 0.155 0.250
Lithuania 1.1 25 6.3 139 0.2 7 0.6 24 0.180 0.292
Luxembourg 3.4 13 2.9 11 0.6 3 1.1 6 1.182 0.500
Norway 2.3 102 1.5 65 0.4 25 0.7 35 1.569 0.714
Sweden 2.1 198 1.5 141 0.4 44 0.7 78 1.404 0.564
Continued
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Eastern Europe. Poland (AAPC −7·1, −12, 1·9) reported a substantial reduction in incidence in men.  Among 
men, Bulgaria (AAPC 2.8, 95% C.I. 0.5, 5.1) had a rise in mortality while Poland (AAPC −2.4, 95% C.I. −3.5, 
−1.3) and Slovakia (AAPC −2.1, 95% C.I. −3.8, −0.4) reported a decline in mortality.
Discussion
This study evaluated the worldwide incidence/mortality rates of oesophageal cancer based on existing data. It was 
found that the incidence and mortality showed wide variations on a global basis. In men, Eastern Asia, Southern 
Africa and Eastern Africa had the highest number of new diagnoses - mostly SCC. The greatest mortality in male 
was found in Middle Africa, Western Africa and Eastern Asia. The highest incidence: mortality ratio was reported 
in Northern and Southern Africa among male, while in Western Europe and Southern America among female.
We found that HDI and GDP per capita were both correlated with AC:SCC ratios in incidence. The correlation 
coefficients for HDI and GPD per capita for the incidence of oesophageal cancer are large. One of the important 
findings includes the incidence decline in Black America, Singapore and China in men and women. In men, 
mortality rates increased drastically in less developed nations including the Philippines and Bulgaria. In women, 
a substantial decrease in mortality was reported for Columbia and Slovenia.
Findings from the present study corroborate those of previous literature. Populations in Asia such as Northern 
Iran28, Central Asia and China29, as well as Eastern Africa30–32, have high incidence rates - so that these regions were col-
lectively named as the “oesophageal cancer belt”10. The higher incidence rates in these regions may reflect the changing 
epidemiology of the two histologic types of esophageal cancer (SCC vs. AC) in recent years, such as in Iran where the 
rates of AC were among the highest in the Central Asian region, particularly in women33. Some nations reported greater 
rates of AC when compared with that of SCC, including Northern/Western Europe and Northern America.
This study showed that nations with higher socioeconomic developement had higher AC:SCC ratio in correlation 
analyses. Poor oral hygiene and poverty have been associated with a higher SCC risk. In addition, there has been rising 
prevalence of obesity (a risk factor for AC)10 but declining tobacco smoking (risk of SCC) in more developed nations, 
which may underpin these correlation trends. Probable explanations for the reduction of mortality trends may consist 
of technological advancement of oesophageal cancer, such as improvements in endoscopic detection and therapy for 
early stage disease. These consist of minimally invasive esophagectomy3–which when accompanied by a strategy with 
conjoint use of laparoscopic and thoracoscopic techniques, can lead to a very low rate of postoperative mortality (1.7% 
Male Female
AC:SCC ratio (male) AC:SCC ratio (female)
AC SCC AC SCC
ASR N ASR N ASR N ASR N
Switzerland 2.6 197 3.3 237 0.5 46 1.4 111 0.831 0.414
The Netherlands 7.1 1102 2.8 433 1.2 237 1.5 276 2.545 0.859
United Kingdom 7.2 4351 2.5 1510 1.4 1120 2 1617 2.881 0.693
Southern Europe
Albania 0.4 9 1.3 26 0.1 3 0.5 12 0.346 0.250
Bosnia Herzegovina 0.4 13 1.3 38 0.1 5 0.5 16 0.342 0.313
Croatia 0.9 32 4.5 168 0.1 9 0.5 33 0.190 0.273
Cyprus 0.8 6 0.6 5 0.2 2 0.3 3 1.200 0.667
Macedonia 0.3 4 0.9 14 0.1 1 0.2 3 0.286 0.333
Greece 0.4 44 1.2 129 0.1 10 0.2 31 0.341 0.323
Italy 0.6 404 1.5 919 0.1 93 0.4 370 0.440 0.251
Malta 2.3 9 1.3 5 0.1 1 0.6 5 1.800 0.200
Montenegro 0.6 3 2.2 10 0.2 1 0.7 3 0.300 0.333
Portugal 1.3 121 4.7 405 0.1 17 0.4 57 0.299 0.298
Serbia 0.6 44 3.4 252 0.1 12 0.7 68 0.175 0.176
Slovenia 0.7 12 3 54 0.1 3 0.5 14 0.222 0.214
Spain 1.3 527 3.1 1209 0.2 93 0.5 234 0.436 0.397
Oceania
Australia 3.4 657 1.9 365 0.5 119 1.1 285 1.800 0.418
Fiji 0.4 2 2.6 10 0.0 0 0 0 0.200 0.000
French Polynesia 0.7 1 4.8 7 0.0 0 0 0 0.143 0.000
Guam 0.4 0 2.5 3 0.0 0 0 0 0.000 0.000
New Caledonia 0.7 1 4.7 7 0.0 0 0 0 0.143 0.000
New Zealand 4.0 150 1.5 57 0.6 27 1.2 60 2.632 0.450
Papua New Guinea 0.5 8 3.5 56 0.3 7 1.6 36 0.143 0.194
Samoa 0.0 0 0 0 0.2 0 1 1 0.000 0.000
Solomon Islands 0.0 0 0.3 1 0.0 0 0 0 0.000 0.000
Vanuatu 0.0 0 0 0 0.0 0 0 0 0.000 0.000
Table 3. The ratio between incidence of adenocarcinoma and squamous cell carcinoma in all countries. AC: 
adenocarcinoma; ASR: age-standardized rate; SCC: squamous cell carcinoma.
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within 30 days) and a reduction in pulmonary complications, when compared with open surgery. With the advances 
in endoscopic surveillance programs after Barrett’s esophagus is diagnosed, physicians could detect more early stage 
cancer and this could facilitate earlier management3. However, some countries including Bulgaria and the Philippines 
Figure 1. (A) Relationship between incidence of oesophageal adenocarcinoma and Human Development 
Index in male (upper panel) and female (lower panel). (B) Relationship between age-standardised incidence 
of oesophageal squamous cell carcinoma and Human Development Index in male (upper panel) and female 
(lower panel). (C) Relationship between age-standardised incidence of oesophageal adenocarcinoma and Gross 
Domestic Product per capita in male (upper panel) and female (lower panel). (D) Relationship between age-
standardised incidence of oesophageal squamous cell carcinoma and Gross Domestic Product per capita in 
male (upper panel) and female (lower panel).
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Figure 2. (A) Relationship between the ratio of age-standardised incidence rates of adenocarcinoma (AC): 
squamous cell carcinoma (SCC) and Human Development Index in male (upper panel) and female (lower 
panel). (B) Relationship between the ratio of age-standardised incidence rates of adenocarcinoma (AC): 
squamous cell carcinoma (SCC) and Gross Domestic Product per capita in male (upper panel) and female 
(lower panel). (C) Relationship between the ratio of crude incidence rates of adenocarcinoma (AC): squamous 
cell carcinoma (SCC) and Human Development Index in male (upper panel) and female (lower panel) (D) 
Relationship between the ratio of crude incidence rates of adenocarcinoma (AC): squamous cell carcinoma 
(SCC) and Gross Domestic Product per capita in male (upper panel) and female (lower panel).
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showed escalating rates of cancer death in women. This observation could be explained by the capacities and acces-
sibility of healthcare services which are crucial for early diagnosis and management. The exact reasons on the rise of 
mortality rates in these countries are yet to be explored. It should be noted that the AC:SCC ratio only exceeded 1 in 
men in most developed nations. SCC was still a predominate type of oesophageal cancer as reported in this study. 
Arnold and colleagues10 previously analyzed the total numbers of AC and SCC in 2012, and reported that SCC was a 
disproportionally common histologic type when compared to AC on a global basis.
This study updated the incidence and mortality of oesophageal cancer, and explored its time trends and global 
variability by high quality data from recognized databases. Nonetheless, this study has some limitations. Firstly, 
cancer diagnoses could be under-reported and may induce bias in cancer registration, particularly in nations 
where resources are limited29. On the other hand, in nations where figures were derived from only one cancer 
registry situated in more developed areas, the estimates might have overestimated the real figures especially in 
those countries with large areas of underdeveloped regions. Also, less than half of the world’s nations provided 
high quality incidence/mortality data. Therefore, the incidence and mortality figures could have a certain degree 
of bias, especially in underprivileged nations.
Figure 3. (A) Incidence trend of oesophageal cancer in male (left panel) and female (right panel). (B) Mortality 
trend of oesophageal cancer in male (left panel) and female (right panel).
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In summary, the incidence of esophageal cancer decreased in the majority of nations, yet the death rates in 
male populations increased in some countries, especially in the Portugal and Bulgaria. With global expansion in 
population size, a further increase in its global health burden could be huge – particularly adenocarcinoma that 
is positively correlated with socioeconomic development. Therefore, more expenditure will be required to sustain 
its diagnosis and treatment. In the community, more resources should also be committed to primary prevention 
strategies.
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